EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Risk‐adapted treatment in multiple myeloma: Does more make it merrier?

Saurabh Zanwar iD, Gliceida M Galarza Fortuna, Douglas W Sborov iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19676 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Saurabh Zanwar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kaiser et al. offer management recommendations for transplant‐eligible, high‐risk multiple myeloma (HRMM), derived from recent trials exploring treatment intensification in the various phases of front‐line therapy. The definition of HRMM continues to evolve with emergence of novel genomic insights and impact of modern therapies, underscoring the need to expand beyond traditional interphase fluorescence in situ hybridization cytogenetics and International Staging System staging for a precise risk assessment. Despite progress, ongoing challenges in treatment delivery and tolerability underscore the urgency for exploring novel approaches like T‐cell redirecting bispecific antibodies and chimeric antigen receptor T‐cell to enhance outcomes in this complex patient population. Commentary on: Kaiser et al. Diagnosis and initial treatment of transplant‐eligible high‐risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper. Br J Haematol 2024; 205:833‐839.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansRisk AssessmentPractice Guidelines as Topic

Stichwörter der Autor:innen

HRMMhigh‐risk multiple myelomaphase 3

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
  • Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.

ORCID-Profile: Saurabh Zanwar, Douglas W Sborov

Zitieren

APA

Zanwar, S., Galarza Fortuna, G. M., & Sborov, D. W. (2024). Risk‐adapted treatment in multiple myeloma: Does more make it merrier?. British Journal of Haematology. https://doi.org/10.1111/bjh.19676

Vancouver

Zanwar S, Galarza Fortuna GM, Sborov DW. Risk‐adapted treatment in multiple myeloma: Does more make it merrier?. British Journal of Haematology. 2024. doi:10.1111/bjh.19676

BibTeX
@article{Zanwar2024,
  author = {Zanwar, Saurabh and Galarza Fortuna, Gliceida M and Sborov, Douglas W},
  title = {Risk‐adapted treatment in multiple myeloma: Does more make it merrier?},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19676}
}
Kostenlos starten →